newsfilter
← Latest News
ACCESS Newswire·

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

Net income of $4.0 million, or $0.65 and $0.21 net income per share basic and diluted, respectivelyAdjusted EBITDA1 of $3.9 millionTotal net revenue of $18.5 million up 32% year-over-yearCompany to host conference call